Search

Your search keyword '"Gertig D"' showing total 138 results

Search Constraints

Start Over You searched for: Author "Gertig D" Remove constraint Author: "Gertig D"
138 results on '"Gertig D"'

Search Results

1. Prognostic gene expression signature for high-grade serous ovarian cancer

2. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

3. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

4. Prognostic gene expression signature for high-grade serous ovarian cancer

5. Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.

6. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

7. Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.

8. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

10. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study

11. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium

12. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

14. Management and long-term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study

16. Spatial variation in cervical cancer screening participation and outcomes among Indigenous and non-Indigenous Australians in Queensland

18. BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition.

19. Spatial variation in cervical cancer screening participation and outcomes among Indigenous and non-Indigenous Australians in Queensland

20. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

21. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

22. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53mutation status in ovarian mucinous tumors: implications for outcome analyses

23. Annexin A1 expression in a pooled breast cancer series: Association with tumor subtypes and prognosis

24. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial

25. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial

26. Progesterone Receptor Promoter +331A Polymorphism is Associated with a Reduced Risk of Endometrioid and Clear Cell Ovarian Cancers

27. The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011)

28. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use

29. Fine-scale mapping of the 4q24 locus identifies & pr two Independent loci associated with breast cancer risk

30. Annexin A1 expression in a pooled breast cancer series: Association with tumor subtypes and prognosis

31. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium

33. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

34. Improving chlamydia knowledge should lead to increased chlamydia testing among Australian general practitioners: A cross-sectional study of chlamydia testing uptake in general practice

35. Skewed X chromosome inactivation and breast and ovarian cancer status: Evidence for X-linked modifiers of BRCA1.

36. Expenditure and resource utilisation for cervical screening in Australia

37. HFE C282Tyr homozygotes with serum ferritin concentrations below 100ug/L are at low risk of hemochromatosis

38. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer

39. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.

40. A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis

41. HFE C282Y/H63D Compound Heterozygotes Are at Low Risk of Hemochromatosis-Related Morbidity

42. Body size and risk of epithelial ovarian and related cancers: A population-based case-control study.

43. Recreational physical activity and epithelial ovarian cancer: A case-control study, systematic review, and meta-analysis.

44. Consortium analysis of 7 candidate SNPs for ovarian cancer.

45. Iron-overload-related disease in HFE hereditary hemochromatosis

46. The Natural History of Serum Iron Indices for HFE C282Y Homozygosity Associated With Hereditary Hemochromatosis

49. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.

50. Genome-wide association study identifies novel breast cancer susceptibility loci.

Catalog

Books, media, physical & digital resources